For US Healthcare Professionals

US Prescribing Information Medication Guide

NOW APPROVED WITH 2 INDICATIONS IN PEDIATRIC PATIENTS

Choose Adult IndicationDrugDrug name X

NVAF Reduce stroke risk
PAD Reduce the risk of major thrombotic vascular events
CAD Reduce the risk of major CV events
VTE Prophylaxis Acutely Ill Medical Patients
DVT/PE Initial treatment
DVT/PE Extended treatment
DVT Prophylaxis After hip/knee replacement surgery

Home
Clinical Trial
Efficacy Profile
Safety Profile
Dosing

Home
Clinical Trials
Efficacy
Safety
Net Clinical Benefit
Summary
Dosing

Home
Clinical Trials
Efficacy Profile
Safety Profile
Dosing

Home
Clinical Trials
Efficacy Profile
Safety Profile
Dosing

Home
Clinical Trial
Efficacy Profile
Safety Profile
Dosing

Home
Clinical Trials
Efficacy Profile
Safety Profile
Dosing

Home
Clinical Trial
Efficacy Profile
Safety Profile
Dosing

Adult Dosing
- NVAF
- CAD/PAD
- DVT/PE
Adult Switch and Management
Access and Support
Resources
- Resources Hub
- FAQs
Pediatric
- VTE (Pediatrics)
- Post Fontan (Pediatrics)

Important Safety Information
US Prescribing Information
Medication Guide
For Non-US Visitors
Patient Site
SEARCH

For

Choose Adult Indication

NVAFReduce stroke risk
PADReduce the risk of major thrombotic vascular events
CADReduce the risk of major CV events
VTE ProphylaxisAcutely Ill Medical Patients
DVT/PEInitial treatment
DVT/PEExtended treatment
DVT ProphylaxisAfter hip/knee replacement surgery

Site Map

Having trouble finding what you want? Try the search field at the top of this page, or use this index.

About XARELTO^®

Switch and Management
Access and Support
Resources
FAQs
Dosing across Indications

NVAF: Reducing Stroke Risk

NVAF Home
Extensive Evidence
Efficacy Profile
Safety Profile
Dosing

PAD: Reduce the Risk of Major Thrombotic Events

PAD Home
Clinical Trials
Efficacy Profile
Safety Profile
Net Clinical Benefit
Summary
Dosing

CAD: Reduce the Risk of Major CV events

CAD Home
Clinical Trial
Efficacy Profile
Safety Profile
Dosing

DVT/PE: Initial Treatment

DVT/PE Initial Home
Extensive Evidence
Efficacy Profile
Safety Profile
Dosing

DVT/PE: Extended Treatment

DVT/PE Extended Home
Clinical Trial
Efficacy Profile
Safety Profile
Dosing

VTE Prophylaxis: Acutely Ill Medical

Acutely Ill Medical Home
Clinical Trial
Efficacy Profile
Safety Profile
Dosing

DVT Prophylaxis: After Knee or Hip Replacement Surgery

DVT Prophylaxis Home
Extensive Evidence
Efficacy Profile
Safety Profile
Dosing

Pediatric

VTE (Pediatric)
Post Fontan (Pediatric)

General

Home
Legal Notice
Privacy Policy
Medical Information Center
Medication Guide
US Prescribing Information
Important Safety Information

Do you want to leave XARELTOhcp.com?

By clicking on “Yes” below, you will leave XARELTOhcp.com.

Clicking on “Yes” below will take you to a website to which our site’s Privacy Policy does not apply. You are solely responsible for your interactions with that website. The links on XARELTOhcp.com are provided for informational purposes only and do not represent an endorsement, direct or implied, of the websites to which you will be directed.

YES NO

Dosing Across Indications
Legal Notice
Privacy Policy
Medical Information Center
Site Map

XARELTO^® is licensed from Bayer HealthCare AG, 51368 Leverkusen, Germany.

This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice | Privacy Policy | Medical Information Center

Do not sell my personal information

Last Updated 3/20/2023